Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Monte Rosa Therapeutics (GLUE) Non-cash Items (2023 - 2025)

Historic Non-cash Items for Monte Rosa Therapeutics (GLUE) over the last 3 years, with Q3 2025 value amounting to $15.8 million.

  • Monte Rosa Therapeutics' Non-cash Items rose 16844.98% to $15.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $15.8 million, marking a year-over-year increase of 16844.98%. This contributed to the annual value of $6.3 million for FY2024, which is 3377.57% up from last year.
  • Per Monte Rosa Therapeutics' latest filing, its Non-cash Items stood at $15.8 million for Q3 2025, which was up 16844.98% from $2.8 million recorded in Q2 2025.
  • In the past 5 years, Monte Rosa Therapeutics' Non-cash Items ranged from a high of $15.8 million in Q3 2025 and a low of $1.8 million during Q2 2024
  • Over the past 3 years, Monte Rosa Therapeutics' median Non-cash Items value was $5.9 million (recorded in 2024), while the average stood at $7.1 million.
  • Its Non-cash Items has fluctuated over the past 5 years, first crashed by 4747.63% in 2024, then surged by 16844.98% in 2025.
  • Quarter analysis of 3 years shows Monte Rosa Therapeutics' Non-cash Items stood at $4.7 million in 2023, then soared by 33.78% to $6.3 million in 2024, then soared by 148.52% to $15.8 million in 2025.
  • Its last three reported values are $15.8 million in Q3 2025, $2.8 million for Q2 2025, and $7.5 million during Q1 2025.